Bio-Hermes

This Nature article highlights how blood-based biomarkers for Alzheimer’s disease stand to have the potential to transform diagnostics, and how new treatments and therapies are developed. There is mention of how Bio-Hermes-001, and Bio-Hermes-002, use head-to-head comparisons of blood-based biomarkers and digital tests to explore which combinations of blood-based biomarkers perform best across different populations and […]

“Changes in memory and cognitive health can start decades before symptoms appear. That’s why early diagnosis and intervention are crucial to slowing impact.  A new paper co-authored by GAP with our partners at Eli Lilly and Company, “Interchangeability of blood-based biomarkers and PET to identify Alzheimer’s disease Pathology” published in Alzheimer’s & Dementia shows that blood biomarkers (P-tau 217 and Precivity AD) have high agreement with […]

“We’re pleased and proud to report our latest paper using Bio-Hermes-001 data has been published in Alzheimer’s & Dementia. Many thanks to the co-authors who helped to bring this research article to light including Richard Mohs, Douglas Beauregard, Lynne Hughes, Cyndy Cordell, Allan Levey, M.D., Ph.D., Saima Rathore, Nicholas Seyfried, Erik Johnson, Jessie Nicodemus-Johnson, Joshua Christensen, and Robin […]

Tori Rodriguez, MA, LPC, AHC Publish DateJanuary 27, 202 At the 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, held December 1 to 4, 2025, in San Diego, California, researchers presented new data spanning observational studies, biomarker analyses, and clinical development programs in Alzheimer disease (AD). Key topics included emerging evidence on metabolic therapies such as […]

The test aims to pick up three proteins known to be associated with Alzheimer’s Jane KirbyMonday 19 January 2026 11:14 GMT Bookmark popover Removed from bookmarksClose popover A pioneering trial has begun to assess whether a simple finger-prick blood test could offer an early diagnosis for Alzheimer’s disease, even before symptoms manifest. Experts are optimistic […]

Washington D.C., Jan 9, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, to the Bio-Hermes studies. This collaboration will enhance the unique, observational platform studies that compare blood-based and digital biomarkers across a broad range of clinical […]

20 Dec ‘It’s the best time’: Family members may notice signs of Alzheimer’s at holiday gatherings Posted at 20:23h in Uncategorized by Belinda Russell 0 Comments ATLANTIS, Fla. — It’s the holiday season and while you celebrate with friends and family some experts say you may also notice some changes in elderly loved ones you haven’t seen for a while. Dr. Linda […]

Aging Emerging biomarkers and digital tools are unlocking earlier and more accurate diagnosis Teresa, 75, an Alzheimer’s patient and former businesswoman, poses for a photograph inside the Alzheimer Foundation, in Mexico City, Mexico, on April 19, 2012.REUTERS/Edgard Garrido by Lydia Wu, Jennifer Panlilio, Melissa Lee, Laura Nisenbaum, Aishu Sukumar December 10, 2025 Alzheimer’s disease and related dementias affect more than […]

Posted on October 2, 2025 • by Julia Ferrar Most biomarker tests, such as PET scans and spinal taps, are expensive or invasive and can pose risks for patients. That’s why a company in the Tampa Bay area is helping to research blood tests for biomarkers as a less expensive and more accessible alternative. Axiom […]

FOX 13’s Allie Corey and her guest discuss Alzheimer’s and the latest research in the disease. Watch the interview with Dr. Steen of Axiom Brain Health here: https://www.fox13news.com/video/1715786

Prevent cognitive decline with these proven lifestyle changes! Join us on PSI TV as Dr. Susan Steen, MD, a renowned neurologist and Alzheimer’s expert, shares groundbreaking insights into brain health. Representing Axiom Brain Health, Dr. Steen discusses their mission to combat neurodegenerative diseases like Alzheimer’s and Parkinson’s through cutting-edge research and clinical trials. Learn how […]

Researchers at Emory Goizueta Brain Health Institute and partner institutions have found new clues in the blood that could help explain why Alzheimer’s disease develops and how it affects memory. The study, published in Nature Aging, examined blood samples from more than 2,100 individuals across four large research cohorts. Using advanced tools, scientists measured thousands of proteins in […]

Story by Ronna Charles • 2 min read Researchers at Emory Goizueta Brain Health Institute and partner institutions have found new clues in the blood that could help explain why Alzheimer’s disease develops and how it affects memory.The study, published in Nature Aging, examined blood samples from more than 2,100 individuals across four large research cohorts. […]

Data from Most Deeply Characterized Cohort Across Alzheimer’s Disease Released byGlobal Alzheimer’s Platform Foundation and Alzheimer’s Disease Data Initiative Washington D.C., July 31, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) and the Alzheimer’s Disease Data Initiative (AD Data Initiative) announced today that data generated from the Bio-Hermes-001 study are now publicly available. This release […]

Showcase on Bio-Hermes Data Challenge and Poster Presentation to Take Place at the Alzheimer’s Association International Conference (AAIC) Washington D.C., July 23, 2025- The Global Alzheimer’s Platform Foundation® , (GAP) will have a poster presentation and a Featured Research Session at the 2025 Alzheimer’s Association International Conference (AAIC) being held in Toronto, Canada. Poster Presentation […]

IXICO joins collaborative study of new biomarkers designed to improve diagnosis of Alzheimer’s disease and dementias  Washington D.C., July 22, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome IXICO, a global leader in neuroscience imaging and biomarker analytics, to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform study […]

Global Researchers Recognized for Trailblazing Projects in First-of-Its-Kind Data Competition Washington D.C., Mar. 27, 2025 – International non-profit organization The Global Alzheimer’s Platform Foundation® (GAP) in collaboration with the Scottish Funding Council’s Brain Health Alliance for Research Challenges (ARC) and the Alzheimer’s Disease Data Initiative proudly announced four winners of the Bio-Hermes Biomarker Data Challenge  at the first Data […]

The Global Alzheimer’s Platform Foundation® (GAP) – which is focused on global game-changing dementia research working with the Scottish Funding Council’s Brain Health Alliance for Research Challenges (ARC)  proudly announces the first-of-its-kind Data Challenge Summit which will unveil the results stemming from the Bio-Hermes-001 Biomarker Data Challenge. The research competition was launched in February of 2024 to allow researchers early access […]

The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce a collaboration with the Biomarkers of Aging Consortium, a consortium dedicated to the developing and validating biomarkers for aging and longevity. Through a memorandum of understanding, the consortium, led by scholars from Harvard University, will gain early access to Bio-Hermes-001 data to investigate the potential for […]

Collaboration to accelerate the investigation of Alzheimer’s disease biomarkers with early access to Bio-Hermes-001 data  Washington D.C., Jan. 30, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce a collaboration with the Biomarkers of Aging Consortium, a consortium dedicated to the developing and validating biomarkers for aging and longevity. Through a memorandum […]

The Global Alzheimer’s Platform Foundation (GAP) is excited to announce its collaboration with Eli Lilly and Company on the transformative Bio-Hermes-002 study. This partnership is poised to broaden the understanding of Alzheimer’s disease by integrating advanced biomarkers that may assist in its early detection and diagnosis. Significance of the Bio-Hermes-002 Study Like its predecessor, Bio-Hermes-001, […]

Oct 30, 2024 | staff reporterSave for later NEW YORK – The Global Alzheimer’s Platform (GAP) Foundation has launched the Bio-Hermes-002 study, in which it will continue to explore biomarkers that can predict the likelihood that a patient has amyloid and tau accumulations in their brains, signaling a potential Alzheimer’s diagnosis. The Alzheimer’s research-focused nonprofit announced the […]

What we do Dementia and Neurodegeneration was identified as one of the key healthcare missions in the 2021 Life Sciences Vision. Dementia is the leading cause of death in England and one in two people will be directly affected by it – either they will care for someone with the condition, develop it themselves, or both. […]

An eye-based Alzheimer’s disease test Routine eye exams could provide data to identify a patient’s disease risk earlier Spotted: Dementia diagnoses appear to be increasing worldwide, most likely from a combination of ageing populations and improved awareness of the disease alongside strengthened diagnostic tools. In Canada, medical AI company RetiSpec uses commonly used eye exam images to diagnose Alzheimer’s […]